Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00034164 | Safety and Efficacy of S-8184 in Second Line Treatment of Relapsed Stage IIIB or IV Non Small Cell Lung Cancer | PHASE2 | COMPLETED | 52 | — | — | Apr 1, 2002 | Sep 1, 2007 | Jun 4, 2009 | 1 | Russia |
| Name | Type | Description |
|---|---|---|
| S-8184 Paclitaxel Injectable Emulsion | DRUG | - |
Inclusion Criteria: Histologic diagnosis of non small cell lung cancer Relapsed or unresectable stage IIIB or IV disease One and only one prior cytotoxic chemotherapy regimen which must have included a platinum agent dosed at 60 mg/m2 or higher per cycle for cisplatin and AUC 6 per cycle for carb...